BRBR — BellRing Brands, Inc. · 2026-09-04 · Verdict: WATCH · Conviction 2

Price $10.40 (yfinance last, 2026-09-03; last full close $10.72 on 2026-09-02) · Mkt cap ~$1.21B (116.3M sh) · EV ~$2.29B · EV/EBIT ~9.5x on FY26 guidance (screen's 6.5x is FY25 trailing) · FCF yield ~12% normalized (screen's 21% is FY25 trailing) · Net debt $1,084M · ADV ~$33M Sources read: 10-K 2025-11-18 (Items 1, 1A, 7), 10-Q 2026-08-04 (Q3 FY26), DEF 14A 2025-12-16, 8-Ks 2026-05-05, 2026-06-24, 2026-07-08, 2026-08-04 with EX-99.1/99.2, Form 4s (12m). No true call transcript was obtainable; the transcript file is the Q3 press release plus supplemental deck.

1. What the business actually does

BellRing sells ready-to-drink protein shakes and powders under Premier Protein and Dymatize (10-K 2025, Item 1). It owns almost no plants: co-manufacturers make nearly everything, the largest supplying 46.3% of Premier Protein RTD shake volume (10-K 2025, Item 1A). It is a marketing and distribution company on rented capacity. Walmart (with Sam's Club), Costco and Amazon were 74.0% of FY2025 net sales (10-K 2025, Item 1). Spun out of Post Holdings in 2022; Post's CEO Robert Vitale chairs the board (8-K 2026-07-08).

2. Why it is mispriced — the edge case

There is not a real one, and that caps this at WATCH. BRBR is a $1.2B NYSE name with $33M average daily volume, 11.1% Vanguard and 9.6% BlackRock ownership (DEF 14A 2025, Beneficial Ownership), and full sell-side coverage. Nothing is hidden. This is a de-rating: a business the market paid a growth multiple for stopped growing profits, and growth holders left. The screen row is stale — FCF yield 21% and EV/EBIT 6.5x both come from FY2025 (operating profit $357.4M, CFO $260.6M; 10-K 2025, Item 7). Buying here is a cyclical call on input costs, not an inefficiency.

3. Unit economics and growth

The collapse is margin, not demand. Nine months to 30 June 2026: net sales $1,706.4M, up 2.3% on volume +4.7% and price/mix -2.4%; adjusted gross margin 26.6% versus 35.6%; Adjusted EBITDA $222.4M versus $364.2M (13.0% versus 21.8%); adjusted EPS $0.81 versus $1.66 (8-K 2026-08-04, EX-99.1). Management cites "significant input cost inflation (inclusive of tariffs) and higher freight," plus $21.3M of inventory charges (a failed-spec supplier ingredient and excess shake bottles).

Demand is fine: the wellness category grew 8% and RTD 11% in the June quarter, Premier Protein RTD consumption grew 6%, household penetration rose to 21.9% and points of distribution +27% (8-K 2026-08-04, EX-99.2, slides 5, 10, 11).

But part of the damage is structural. Premier Protein RTD tracked dollar share finished Q3 at 21.9%, down from 23.8% at the start of the charted period (8-K 2026-08-04, EX-99.2, slide 12) — slower than an 11% category, so share is lost while shelf space is added. Growth is bought: RTD price/mix was -1.9% in Q3, -4.7% over nine months. And club, home of the largest customers, fell 7.6% in the quarter (EX-99.2, slide 7). With 74% of sales in three retailers and no owned manufacturing, pricing power is asymmetric.

4. Balance sheet and capital allocation

At 30 June 2026: long-term debt $1,135.3M against cash $50.4M and a stockholders' deficit of $(467.2)M (8-K 2026-08-04, EX-99.1). Debt is 7.00% notes due March 2030 plus a $500M revolver; the covenant is net leverage below 6.00:1.00 and the company was compliant (10-Q 2026-08-04, Debt Covenants). Against guided FY26 Adjusted EBITDA of $275-295M, leverage is roughly 3.8x. A separate $90.0M Joint Juice accrual is due in the September 2026 quarter (10-K 2025, Item 1A; 10-Q 2026-08-04).

Capital allocation is the ugliest fact: 9.0M shares bought at an average $52.62 in FY2025 ($476.6M) and 4.9M at $27.41 in nine months of FY2026 ($134.5M), largely revolver-funded (10-K 2025, Item 7; 10-Q 2026-08-04, Liquidity). Roughly $611M spent near an average $44 on a stock now at $10.40, which is why an asset-light business carries $1.08B of net debt. Inventories rose to $480.6M from $330.4M on 2% sales growth, so nine-month operating cash flow fell to $65.0M from $91.5M. Directors and officers own 1.5% as a group (DEF 14A 2025); insiders were net sellers of about $226K over twelve months against one meaningful buy, 4,000 shares at $9.23 by director David Finkelstein (Form 4, 2026-05-13).

5. Management: said versus did

In May the outgoing CEO said guidance already incorporated "promotional and consumer headwinds through the balance of the year, along with incremental inflation on protein and freight" (8-K 2026-05-05, Davenport). Three months later Adjusted EBITDA guidance was cut again, $315-335M to $275-295M (8-K 2026-05-05 and 2026-08-04, Outlook). Two cuts that size mean management lacks a reliable read on its own cost base. The CEO and Chief Growth Officer are both gone (8-K 2026-06-24; 8-K 2026-07-08). New CEO Michael Axelrod, from private Snak King and Del Real Foods, started 29 July 2026 and signed on day one a change-of-control transaction bonus and a Section 4999 excise tax gross-up (8-K 2026-07-08). Boards do not paper those when a sale is inconceivable.

6. Valuation

Base (45%): FY27 sales $2.45B, margin recovers to 14% as $10-12M of realignment savings land (8-K 2026-06-24) and pricing catches up; $343M at 9x EV/EBITDA less $1.05B net debt gives about $17. Bear (35%): margin stays 12%, sales flat at $2.35B; $282M at 7x on leverage concern gives about $7. Bull (20%): protein and freight normalize and margin reaches 18%, below FY25's 21.8%, on $2.55B of sales; $459M at 10x gives about $31. Probability-weighted, roughly $16.50 against $10.40.

Reverse DCF: at $10.40 the ~$2.29B EV capitalizes about $215M of unlevered free cash flow (guided EBITDA $285M less $10M capex and ~$60M cash tax) at a 10% discount rate — the price implies this year's trough 12% margin is permanent and the business never grows again.

7. Catalysts and timeline

Q4 FY26 results and the first FY27 guide from the new CEO, expected November 2026, is the event that matters. The $90M legal payment clears in the September quarter, and protein and freight relief, if it comes, shows in the March 2027 gross margin. A sale is live optionality.

8. Risks and pre-registered kill criteria

Kill the thesis if: (1) adjusted gross margin stays below 29% for both Q4 FY26 and Q1 FY27; (2) Premier Protein RTD tracked dollar share prints below 21% for two consecutive quarters while the RTD category grows more than 5%; (3) reported net leverage exceeds 4.5x or the revolver is drawn beyond $400M; (4) FY27 Adjusted EBITDA guidance in November 2026 lands below $300M. Other risks: a sole aseptic packaging supplier for the 11oz format (10-K 2025, Item 1A) and Joint Juice claims beyond the accrual.

9. Verdict and one-paragraph summary

WATCH, conviction 2. BellRing is a good brand in a growing category whose profits have been roughly halved by input cost inflation, tariffs, freight and self-inflicted inventory charges, and whose stock fell from $43.02 to about $10 in twelve months. The screen flagged it on stale FY2025 numbers: at today's price it trades near 8x EV to guided EBITDA and about a 12% normalized free cash flow yield, which is fair rather than obviously cheap. Two things stop this being an idea. There is no informational edge in a well covered, liquid, institutionally owned mid cap where everyone reads the same guidance cuts. And the margin problem is not purely cyclical: Premier Protein is losing share to a category growing 11%, price/mix is negative, club is shrinking, 74% of sales sit with three retailers, and there is no owned manufacturing to defend margin with. Management also burned roughly $611M on buybacks near an average $44 and left $1.08B of net debt behind. Wait for November 2026: if gross margin inflects above 29% and the new CEO guides FY27 above $300M of EBITDA, the $17 base case becomes defensible and this converts to an idea.

Research for discussion, not investment advice. Positions and sizing are the reader's decision.